Novo Holdings

Novo Holdings is pleased to announce that our portfolio company Kate Farms has been acquired by Danone, a global leader in food and nutrition.   Since our first investment in 2022, we have supported Kate Farms in expanding access to its high-quality, plant-based clinical nutrition, serving patients with complex medical needs as well as individuals seeking better everyday health.   This transaction highlights the role of our Planetary Health Investments team in backing innovative, growth-stage companies to scale their impact. With Danone’s global reach and Brett Matthews continuing as CEO, Kate Farms will further advance its mission and grow its reach both in the U.S. and internationally. Learn more: https://lnkd.in/eyxYWXSZ #Nutrition #PlanetaryHealth #Biotech #LifeSciences

Novo Holdings is pleased to announce the appointment of Dr Joachim Kreuzburg to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its life science investments. Joachim Kreuzburg brings more than two decades of executive experience from the life science technology sector.

Novo Holdings Asia is looking for an ambitious and proactive Associate to join our newly established India team. Based in Mumbai, the Associate will play a key role in sourcing, evaluating, executing and managing investments in the healthcare and life science industry. https://lnkd.in/eVXgwpeF

We are looking for a Junior Analyst to support the Risk and Compliance team and contribute to the day-to-day regulatory operations out of our Copenhagen office. As a Junior Analyst you will be an integral part of this growing function and gain valuable insight into how compliance frameworks are developed and applied in a global investment firm https://lnkd.in/dVs9nxaZ

Novo Holdings is pleased to announce the appointment of Jigar Shah to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its planetary health investments.   With more than 25 years of experience advancing clean energy innovation, Jigar Shah has broad expertise in energy infrastructure financing, entrepreneurship as well as policy insight.

In 2024, our Asia Investments team continued to back innovative companies advancing healthcare access, digital diagnostics, and sustainable food systems across the region. Highlights from the year include our largest-ever Asia investment in Manipal Hospitals (MHEPL), the first Planetary Health investment in Asia with AGNEXT Technologies, pre-IPO support for Medi Assist, and follow-on funding for Qure.ai and MEDGENOME. We also expanded our Shanghai office, co-hosted a Partnering Day in Korea with Novo Nordisk, and deepened community engagement across our markets. Read more in the Asia Investments Year in Review: https://lnkd.in/g6NDZkvP #NovoHoldings #AsiaInvestments #HealthcareInnovation #PlanetaryHealth #LifeSciences

We are looking for a Senior Valuation Specialist to join our Valuation team in Copenhagen. As a Senior Valuation Specialist, you will play a critical role in supporting the leadership’s decision-making process by ensuring accurate and fair valuations of the investments in Novo Holdings’ diverse portfolio. In addition to the Novo Group companies, our growing investment portfolio of more than DKK 200 billion spans across life science companies at all stages of development, as well as a wide selection of public and private equities, bonds, real estate and infrastructure investments. https://lnkd.in/dCy9cnx5

We are looking for a Risk & Performance Analyst to join our Risk & Compliance team in Copenhagen. As a Risk & Performance Analyst, you will play a pivotal role in monitoring and reporting risk and performance across all our investment areas—spanning both public and private markets. https://lnkd.in/eF_qfRey

We are looking for a Market Risk Quant to join our Risk & Compliance team in Copenhagen. As a Market Risk Quant, you will become an expert in the field of market and investment risk, harnessing the state-of-the-art approaches in quantitative analytics. The role will cover all our investment areas, spanning both public and private spheres.  https://lnkd.in/eYJZfD3g

Novo Holdings led GlycoEra AG’s $130M Series B financing, which will support the advancement of the company’s first-in-class extracellular protein degrader – GE8820 – which targets pathogenic IgG4 autoantibodies.   GE8820 has shown deep and sustained IgG4 degradation in preclinical models, offering a highly selective and transformative approach to treating conditions such as pemphigus, MuSK myasthenia gravis, and autoimmune encephalitis. In association with this investment, Novo Holdings Partner Max Klement will join GlycoEra’s Board of Directors to support the company through its evolution from a platform innovator to a clinical-stage biotech advancing multiple products across its pipeline.   Learn more about GlycoEra here: https://lnkd.in/d2D99vhi   #VentureInvestments #Biotech #LifeSciences